Verona Pharma plc Pdmr Dealing

 
TIDMVRP TIDMVRP 
 
 
   LONDON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) 
(NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on developing and commercializing innovative therapies 
for respiratory diseases, announces that, on August 17, 2017, Dr. David 
Ebsworth, Non-Executive Chairman of the Company, purchased 8,130 
ordinary shares of 5 pence each in the Company (the "Ordinary Shares") 
at a price of 122.5 pence per Ordinary Share.  Following the acquisition, 
Dr. Ebsworth will have an interest in the Company of 125,787 Ordinary 
Shares, representing 0.12% of the Company's issued share capital. 
 
   The notification of dealing form can be found below. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                             Tel: [phone] 
Jan-Anders Karlsson, Chief Executive Officer  [e-mail] 
 
N+1 Singer (Nominated Adviser and UK Broker)  Tel: [phone] 
Aubrey Powell / James White 
 
FTI Consulting (UK Media and Investor         Tel: [phone] 
enquiries) 
Simon Conway / Natalie Garland-Collins        [e-mail] 
 
ICR, Inc. (US Media and Investor enquiries) 
Darcie Robinson                               Tel: [phone] 
                                               [e-mail] 
Stephanie Carrington                          Tel. [phone] 
                                               [e-mail] 
 
 
 
 
 
 
 
1   Details of the person discharging managerial responsibilities/person 
     closely associated 
a)  Name                      David Ebsworth 
2   Reason for the notification 
a)  Position/status           Non-Executive Chairman 
b)  Initial                   Initial notification 
    notification/Amendment 
3   Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
a)  Name                      Verona Pharma plc 
b)  LEI                       213800EVI6O6J3TIAL06 
4   Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place 
     where transactions have been conducted 
a)  Description of the        Ordinary Shares of 5 pence each 
    financial instrument, 
    type of instrument 
    Identification code       GB00BYW2KH80 
b)  Nature of the             David Ebsworth purchased 8,130 Ordinary Shares 
    transaction 
c)  Price(s) and volume(s)            Price(s)                 Volume(s) 
                              122.5 pence per Ordinary   8,130 Ordinary Shares 
                              Share 
 
d)  Aggregated information    N/A 
    - Aggregated volume 
    - Price 
 
e)  Date of the transaction   17 August 2017 
f)  Place of the transaction  London Stock Exchange, AIM 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Verona Pharma plc via Globenewswire 
 
 
  http://www.veronapharma.com/ 
 

(END) Dow Jones Newswires

August 21, 2017 05:41 ET (09:41 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.